Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 23Terminated 7Unknown 3Recruiting 3Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 79OTHER 78NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 19Prostatic Neoplasms 15Multiple Myeloma 15Carcinoma, Non-Small-Cell Lung 12Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma 9Leukemia, Myeloid, Acute 7Lung Neoplasms 6Leukemia, Biphenotypic, Acute 6Squamous Cell Carcinoma of Head and Neck 5Neuroblastoma 5Medulloblastoma 5Lymphoma, Mantle-Cell 5Leukemia 5Hodgkin Disease 5Ependymoma 5Colorectal Neoplasms 5Oropharyngeal Neoplasms 4Neoplasm Metastasis 4Myelodysplastic Syndromes 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Burkitt Lymphoma 4Wilms Tumor 3Urinary Bladder Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Oligodendroglioma 3Melanoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

Fulvestrant 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × NETWORK × Recurrence × Clear all
NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡